【摘要】 目的探讨骨质疏松性骨折经皮椎体后凸成形术后应用唑来膦酸的临床疗效。方法将82例骨质疏松性椎体压缩性骨折患者分为两组,分别为经皮椎体后凸成形术(PKP)组和PKP+唑来膦酸组,唑来膦酸治疗后1周及12个月对两组进行随访,并根据疼痛视觉模拟评分(VAS)、骨密度对治疗效果进行评价。结果唑来膦酸治疗后1周,PKP+唑来膦酸组VAS评分(3.35±0.81)与PKP组(3.28±0.78)比较,差异无显著性意义(P>0.05);治疗后12个月,PKP+唑来膦酸组VAS评分明显低于PKP组(P<0.05)。PKP组治疗后股骨近端骨密度(BMD)值与治疗前比较差异无显著性意义(P>0.05),PKP+唑来膦酸组治疗后BMD较治疗前明显提高(P<0.05);PKP+唑来膦酸组治疗后BMD与PKP组比较明显增高,差异有显著性意义(P<0.05)。结论骨质疏松性骨折经皮椎体后凸成形术后应用唑来膦酸能明显降低腰背部疼痛,提高骨密度,并能遏制骨质疏松症的进一步发展。更多还原

【Abstract】 Objective To investigate the clinical effects of zoledronic acid after percutaneous kyphoplasty for osteoporotic vertebral compression fractures. Methods Eighty- two patients with osteoporotic vertebral compression fractures were randomly divided into 2 groups: the group given percutaneous kyphoplasty( PKP),and the group given PKP +zoledronic acid. All patients were followed up at 1 week and 12 month and were evaluated according to the VAS pain score standard and bone mineral density( BMD) measurement. Results At the first week after therapy,the VAS score in the group given PKP + zoledronic acid was 3. 35 ± 0. 81,which was similar to that in the group given PKP( 3. 28 ±0. 78),P > 0. 05. At the 12 th month after therapy,the VAS score in the group given PKP + zoledronic acid were significantly lower than that in the group given PKP( P < 0. 05). The BMD in group given PKP showed no significant difference before and after the therapy( P > 0. 05),while the BMD in group given PKP + zoledronic acid after the therapy was significantly higher compared with that before the therapy( P < 0. 05). There was significant difference in BMD between group given PKP + zoledronic acid and group given PKP after the therapy( P < 0. 05). Conclusion Application of zoledronic acid after PKP could obviously alleviate pain of the osteoporotic vertebral compression fractures,improve the bone mineral density,and prevent further development of osteoporosis.更多还原